The glaucoma subspecialist who lost the Prairie Eye Center case walked out of his employer's practice in central Illinois thinking the worst possible outcome was a few uncomfortable months and an unpleasant attorney letter. What he walked into instead was a permanent injunction, $1,654,700 in damages, and $164,432.34 in attorney's fees. The court also enforced a clause in his employment agreement that extended the noncompete restriction by the length of the breach period, which reset the clock every time he saw a patient within the restricted geography. The Prairie Eye Center Ltd. v. Butler decision stands as a benchmark for what a badly negotiated ophthalmology noncompete can cost.

Most residents signing their first employment agreement in 2026 have never heard of the case. Most have never read the noncompete language in their own contract past the first paragraph, where the restriction usually sounds reasonable and geographically contained. The first ophthalmology contract a physician signs determines the shape of the next decade of their career, and the clauses that actually drive that shape are rarely the ones the recruiter walks through during the offer conversation.

The Ophthalmology Non-Compete Landscape Changed Twice in 2025

As of April 2026, the federal non-compete rule is dead. The FTC finalized a rule in April 2024 that would have banned most noncompetes nationwide. In August 2024, the Northern District of Texas set the rule aside in Ryan, LLC v. FTC. In September 2025, the FTC voted 3-1 to dismiss both appeals and accede to the vacatur. What that means for a resident signing a contract in 2026 is that the federal safety net physicians were counting on during the 2024 rulemaking window no longer exists.

What replaced it is a state-by-state patchwork that moves faster than most employment attorneys track. California, North Dakota, Oklahoma, and Minnesota have full noncompete bans. Texas SB 1318, effective September 1, 2025, capped physician noncompetes at 1 year with a 5-mile radius and a buyout capped at the physician's total annual salary and wages. Several other states have pending physician noncompete legislation that could reshape enforcement during the life of any contract signed this year, which means the same agreement might be unenforceable in 2028 that was fully binding in 2026.

The geography where you practice matters as much as what you sign. Three specific clauses in the actual contract language carry most of the risk regardless of state: duration beyond 2 years in any specialty, geographic radius above 25 miles in urban markets, and any provision that extends the restriction by the length of any breach. That last clause is what turned the Prairie Eye Center case into a seven-figure judgment rather than a walk-away dispute, and some version of it still sits in a surprising number of ophthalmology employment agreements.

Tail Coverage Is the Ophthalmology Exit Cost Nobody Mentions at the Offer Stage

Malpractice insurance structured as claims-made, which is the standard for almost every ophthalmology employer, requires tail coverage when the physician leaves. Tail is an extended reporting endorsement that covers claims filed after the policy ends for events that occurred during the policy period, and the industry rule of thumb prices it at 1.5 to 3 times the mature annual premium, with 2 times being typical.

OMIC, the AAO-endorsed carrier, has published mature rates in the range of approximately $9,900 per year for $1 million in coverage on a full-surgery full-time ophthalmologist. Tail on that policy typically runs $8,000 to $20,000. In higher-premium geographies like New York, Florida, and Illinois, or for subspecialties like retina and oculoplastics with cosmetic work, the tail figure can push toward $30,000 to $150,000, and the physician pays it out of pocket with post-tax dollars. OMIC offers a free tail at retirement if the physician has been continuously insured for 5 years or more. Most other carriers don't, which means the tail charge becomes a real number for every ophthalmologist who leaves a job before the carrier's long-tenure threshold.

The question of who pays the tail is typically buried in the employment agreement in language that reads like standard boilerplate. For a physician leaving at year 3 to take a better opportunity, the tail payment can be the single largest out-of-pocket cost of the move. For a physician leaving under duress, whether through termination without cause or what the lawyers call constructive termination, the tail figure becomes a leverage point the employer uses to discourage the departure entirely.

The Ophthalmology Partnership Track Question That Almost Never Gets Answered Honestly

John Pinto has been advising ophthalmology practices for more than three decades, and his published observation is that roughly 50% of partner-track associates in ophthalmology actually convert to partnership. The typical track runs 2 years for ophthalmology, with the associate either being offered partnership at year 2 or continuing as an employed physician indefinitely, and the 50% conversion rate comes from a structural issue rather than underperformance.

Partnership track language in employment agreements is usually aspirational rather than mechanical. "Eligible for partnership consideration" is enforceable only as a promise of consideration, while "will be offered partnership at the conclusion of year 2 at a buy-in price equal to 2.5 times EBITDA" is an actual structural commitment. The difference between those two phrasings can be the difference between a 30-year career arc and a 3-year dead end, and the gap rarely gets flagged by the physician's attorney because it reads like normal contract language.

The associate signing a first agreement in 2026 faces an additional dynamic that didn't exist 15 years ago. Senior partners anticipating a PE exit have a direct financial incentive to delay partnership, because every partner added reduces the equity stake of existing partners at the eventual sale. The associate who joins a group in 2026 expecting a year-2 partnership track can easily find themselves in year 4, still employed, while the senior partners quietly negotiate a platform transaction that captures the goodwill the associate spent two years building. Residents evaluating a partnership track need to ask directly whether the practice is in any active or preliminary conversations about a platform deal, and they need to get the answer in writing.

The Retention Equity Clause That Determines Whether an Ophthalmologist Gets Paid at the Second Exit

PE-backed ophthalmology employers build retention equity into employment agreements specifically as a tool for managing physician turnover. The structure typically includes a 4-year vesting period with a 1-year cliff, performance-based vesting tied to EBITDA or MOIC targets, and bad leaver clauses that forfeit unvested equity if the physician leaves for reasons the employer defines as cause.

Goodwin's 2024 survey of PE portfolio company equity trends found that in a bad leaver scenario, 75% of rollover equity gets repurchased at the lower of cost or fair market value, meaning the physician gets the original investment back minus all appreciation. In that same scenario, 100% of incentive equity gets forfeited. Bass Berry's analysis of physician practice management transactional structure noted that a common cash clawback provision recovers 20% per year if the physician stays less than approximately 5 years, which means a physician who leaves at year 3 can be writing the employer a check for 40% of what they were paid in retention cash during the prior two years.

A physician signing a first contract with a retention equity component needs to understand three things: which trigger events count as bad leaver versus good leaver, what happens to vested equity at a change of control, and whether the vesting schedule resets at the platform's secondary sale. That last question is the one most residents never think to ask, and the answer is almost always yes, which extends the retention period by another 4 to 5 years every time the platform changes hands. An ophthalmologist who joins a PE-backed group in 2026 expecting to vest fully by 2030 can find the vesting clock restart in 2028 when the sponsor sells to a larger platform, and restart again in 2032 when the second sponsor sells.

The clauses that determine whether an early-career ophthalmologist actually captures the retention equity they were recruited with are typically 3 pages deep in the purchase agreement rather than the employment agreement. The offer letter shows the headline number. The realization mechanics live in documents the physician rarely sees until they need to understand them, which is usually too late. The residents who read every page of every document before signing are rare, and the residents who have the leverage to negotiate what they find in those pages are rarer still.

This article is for general educational purposes and is not legal or financial advice.

Verdira is a healthcare acquisition platform focused on ophthalmology practices. Physician ownership. Transparent structure. No volume quotas. If you're a resident, fellow, or early-career ophthalmologist exploring ownership, we're open to thoughtful conversations.

Contact info@verdira.com | 307-381-3734 | verdira.com